SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:lup.lub.lu.se:0c554e6e-df79-452c-86c3-29086e5da412"
 

Search: id:"swepub:oai:lup.lub.lu.se:0c554e6e-df79-452c-86c3-29086e5da412" > Exploring IL-17 in ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Groen, Solveig SkovlundUniversity of Copenhagen,Nordic Bioscience AS (author)

Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • Elsevier BV,2021

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:0c554e6e-df79-452c-86c3-29086e5da412
  • https://lup.lub.lu.se/record/0c554e6e-df79-452c-86c3-29086e5da412URI
  • https://doi.org/10.1016/j.autrev.2021.102760DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:for swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Spondyloarthritis (SpA) is an umbrella term describing a family of chronic inflammatory rheumatic diseases. These diseases are characterised by inflammation of the axial skeleton, peripheral joints, and entheseal insertion sites throughout the body which can lead to structural joint damage including formation of axial syndesmophytes and peripheral osteophytes. Genetic evidence, preclinical and clinical studies indicate a clear role of interleukin (IL)- 23 and IL-17 as mediators in SpA pathogenesis. Targeting the IL-23/−17 pathways seems an efficient strategy for treatment of SpA patients, and despite the remaining challenges the pathway holds great promise for further advances and improved therapeutic opportunities. Much research is focusing on serological markers and imaging strategies to correctly diagnose patients in the early stages of SpA. Biomarkers may facilitate personalised medicine tailored to each patient's specific disease to optimise treatment efficacy and to monitor therapeutic response. This narrative review focuses on the IL-17 pathway in SpA-related diseases with emphasis on its role in pathogenesis, current approved IL-17 inhibitors, and the need for biomarkers reflecting core disease pathways for early diagnosis and measurement of disease activity, prognosis, and response to therapy.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sinkeviciute, DovileLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Molekylär skelettbiologi,Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Molecular Skeletal Biology,Lund University Research Groups,Nordic Bioscience AS(Swepub:lu)do6165si (author)
  • Bay-Jensen, Anne ChristineNordic Bioscience AS (author)
  • Thudium, Christian S.Nordic Bioscience AS(Swepub:lu)med-ctu (author)
  • Karsdal, Morten A.Nordic Bioscience AS (author)
  • Thomsen, Simon FrancisBispebjerg Hospital,University of Copenhagen (author)
  • Schett, GeorgFriedrich-Alexander University Erlangen-Nürnberg (author)
  • Nielsen, Signe HolmTechnical University of Denmark,Nordic Bioscience AS (author)
  • University of CopenhagenNordic Bioscience AS (creator_code:org_t)

Related titles

  • In:Autoimmunity Reviews: Elsevier BV20:31568-9972

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view